197 related articles for article (PubMed ID: 16449697)
1. Schizophrenia, neuroleptic medication and mortality.
Joukamaa M; Heliövaara M; Knekt P; Aromaa A; Raitasalo R; Lehtinen V
Br J Psychiatry; 2006 Feb; 188():122-7. PubMed ID: 16449697
[TBL] [Abstract][Full Text] [Related]
2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.
Baandrup L; Gasse C; Jensen VD; Glenthoj BY; Nordentoft M; Lublin H; Fink-Jensen A; Lindhardt A; Mortensen PB
J Clin Psychiatry; 2010 Feb; 71(2):103-8. PubMed ID: 19895781
[TBL] [Abstract][Full Text] [Related]
4. Mortality and its determinants in people with psychotic disorder.
Suvisaari J; Partti K; Perälä J; Viertiö S; Saarni SE; Lönnqvist J; Saarni SI; Härkänen T
Psychosom Med; 2013 Jan; 75(1):60-7. PubMed ID: 23257931
[TBL] [Abstract][Full Text] [Related]
5. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.
Goff DC; Sullivan LM; McEvoy JP; Meyer JM; Nasrallah HA; Daumit GL; Lamberti S; D'Agostino RB; Stroup TS; Davis S; Lieberman JA
Schizophr Res; 2005 Dec; 80(1):45-53. PubMed ID: 16198088
[TBL] [Abstract][Full Text] [Related]
6. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).
Tiihonen J; Lönnqvist J; Wahlbeck K; Klaukka T; Niskanen L; Tanskanen A; Haukka J
Lancet; 2009 Aug; 374(9690):620-7. PubMed ID: 19595447
[TBL] [Abstract][Full Text] [Related]
7. Mortality in people with psychotic disorders in Finland: A population-based 13-year follow-up study.
Keinänen J; Mantere O; Markkula N; Partti K; Perälä J; Saarni SI; Härkänen T; Suvisaari J
Schizophr Res; 2018 Feb; 192():113-118. PubMed ID: 28499768
[TBL] [Abstract][Full Text] [Related]
8. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
9. Causes of premature mortality in schizophrenia: a review of literature published in 2018.
Laursen TM
Curr Opin Psychiatry; 2019 Sep; 32(5):388-393. PubMed ID: 31135491
[TBL] [Abstract][Full Text] [Related]
10. Neuroleptics and mortality: a 50-year cycle: Invited commentary on... Schizophrenia, neuroleptic medication and mortality.
Healy D
Br J Psychiatry; 2006 Feb; 188():128. PubMed ID: 16449698
[No Abstract] [Full Text] [Related]
11. Predictors of death from natural causes in schizophrenia: 10-year follow-up of a community cohort.
Brown S; Mitchell C
Soc Psychiatry Psychiatr Epidemiol; 2012 Jun; 47(6):843-7. PubMed ID: 21559973
[TBL] [Abstract][Full Text] [Related]
12. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
Meyer JM; Nasrallah HA; McEvoy JP; Goff DC; Davis SM; Chakos M; Patel JK; Keefe RS; Stroup TS; Lieberman JA
Schizophr Res; 2005 Dec; 80(1):9-18. PubMed ID: 16125372
[TBL] [Abstract][Full Text] [Related]
13. Excess early mortality in schizophrenia.
Laursen TM; Nordentoft M; Mortensen PB
Annu Rev Clin Psychol; 2014; 10():425-48. PubMed ID: 24313570
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up.
Kiviniemi M; Suvisaari J; Koivumaa-Honkanen H; Häkkinen U; Isohanni M; Hakko H
Schizophr Res; 2013 Oct; 150(1):274-80. PubMed ID: 23953217
[TBL] [Abstract][Full Text] [Related]
15. Schizophrenia and smoking: an epidemiological survey in a state hospital.
de Leon J; Dadvand M; Canuso C; White AO; Stanilla JK; Simpson GM
Am J Psychiatry; 1995 Mar; 152(3):453-5. PubMed ID: 7864277
[TBL] [Abstract][Full Text] [Related]
16. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients.
Montout C; Casadebaig F; Lagnaoui R; Verdoux H; Philippe A; Begaud B; Moore N
Schizophr Res; 2002 Oct; 57(2-3):147-56. PubMed ID: 12223245
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of spontaneous dyskinesia in schizophrenia.
Fenton WS
J Clin Psychiatry; 2000; 61 Suppl 4():10-4. PubMed ID: 10739325
[TBL] [Abstract][Full Text] [Related]
19. Altered metabolic parameters in association with antipsychotic medication use in diabetes: A population based case-control study.
Wake DJ; Broughton P; Perera SM; MacIntyre DJ; Leese GP
Psychoneuroendocrinology; 2016 Apr; 66():214-20. PubMed ID: 26849203
[TBL] [Abstract][Full Text] [Related]
20. Excess mortality among long-stay psychiatric patients in Northern Finland.
Räsänen S; Hakko H; Viilo K; Meyer-Rochow VB; Moring J
Soc Psychiatry Psychiatr Epidemiol; 2003 Jun; 38(6):297-304. PubMed ID: 12799779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
